Edwards Life Sciences Corp. (EW): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Edwards Life ( EW) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.6%. By the end of trading, Edwards Life rose $2.63 (2.7%) to $100.43 on average volume. Throughout the day, 950,945 shares of Edwards Life exchanged hands as compared to its average daily volume of one million shares. The stock ranged in a price between $98.10-$101.50 after having opened the day at $98.17 as compared to the previous trading day's close of $97.80. Other companies within the Health Care sector that increased today were: IntelliPharmaCeutics International ( IPCI), up 15.5%, Thermogenesis Corporation ( KOOL), up 13.9%, Clovis Oncology ( CLVS), up 11.9%, and Alliance HealthCare Services ( AIQ), up 10.4%.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases or critically ill patients worldwide. Edwards Life has a market cap of $11.6 billion and is part of the health services industry. The company has a P/E ratio of 46.1, below the average health services industry P/E ratio of 48.2 and above the S&P 500 P/E ratio of 17.7. Shares are up 38% year to date as of the close of trading on Thursday. Currently there are nine analysts that rate Edwards Life a buy, no analysts rate it a sell, and seven rate it a hold.

TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Pluristem Therapeutic ( PSTI), down 12.6%, Aoxing Pharmaceutical Company ( AXN), down 12.5%, Prima Biomed Ltd. ADR ( PBMD), down 11.8%, and Bovie Medical Corporation ( BVX), down 10.8%, were all laggards within the health care sector with Bristol-Myers Squibb Company ( BMY) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).